Importantly, we showed that treatment of Akt-inhibitor-resistant cells with Gefitinib sensitized them to the Akt inhibitor, suggesting potential strategy to overcome resistance to Akt inhibition in luminal breast cancer. Here, AKT1 is linked to breast carcinoma.